Objective: We hypothesize that trafficking of vitamin D is altered in dysfunctional AT.
The high prevalence of vitamin D deficiency in obese subjects (3) suggests that adipose tissue (AT) has a major role in the body distribution of vitamin D, but the causal relationship between obesity and low levels of circulating 25(OH)D has not been completely elucidated yet. To this regard, as suggested from studies in humans and animal models receiving high doses of oral vitamin D3 (4, 5) , it has been proposed that vitamin D, being fat soluble, could be sequestered in body fat depots, leading to lower bioavailability in the obese state (5, 6 ). An alternative hypothesis considers low serum 25(OH)D in obese as a result of volumetric dilution of vitamin D in the large adipose stores (7) .
Taken together, these results suggest that body mass index (BMI) should be taken into account when determining the vitamin D intake required for optimal status (8, 9) . Moreover, although fat depots mainly consist of cholecalciferol, 25(OH)D is widely distributed in many tissues, with the highest concentrations in serum (10) . On these bases, we can understand why orally administrated vitamin D3 has a lower impact on 25(OH)D levels in obese subjects (5, 11) , as it is markedly stored in AT (12) .
This scenario is further complicated by the altered molecular phenotype featuring AT in obesity-induced inflammation and insulin resistance (13) . The catecholamine and natriuretic peptide lipolytic resistance in both obese patients (14) and insulin-resistant (IR) adipocytes (15) may lead to a reduced release of vitamin D from AT. Indeed, not only vitamin D is stored in AT, but it is slowly released into circulation (16) . However, the mechanisms controlling the deposition and release of vitamin D from AT are still unknown (17) . It is likely that, because vitamin D is a fat-soluble secosteroid, it is subjected to the same pathway of cathecolamine-induced lipolysis observed for cholesterol (18) .
Moreover, both human and murine adipocytes express vitamin D-metabolizing enzymes [reviewed by Ding et al. (19) ], suggesting that AT not only passively accumulates vitamin D, but also changes its metabolism in obesity.
Despite the well-established relationship between obesity and low vitamin D, few experimental studies have investigated the biological processes involved in vitamin D metabolism in AT, with conflicting results (10, 20) .
We hypothesized that AT is capable of vitamin D uptake, but in the pathological state the lipolysis-mediated release of vitamin D is impaired, concomitantly with an altered enzymatic machinery. On these bases, we would expect that 25-hydroxyvitamin-D3 rather than vitamin D3 is a more adequate supplementation in obese subjects. Thus, we investigated the following: (1) whether D3 and 25(OH)D are differentially accumulated and released after adrenaline-induced lipolysis in control and IR 3T3-L1 adipocytes; (2) whether vitamin D-metabolizing enzymes are impaired in IR adipocytes; (3) the concentrations of vitamin D3 and 25(OH)D in ex vivo subcutaneous AT (SAT) from normal weight and obese subjects before and after lipolytic stimulation; and (4) whether supplementation with 25(OH)D is more effective in achieving vitamin D sufficiency in obese subjects, compared with vitamin D3.
Methods

Cell culture
The 3T3-L1 cells (American Type Culture Collection, Manassas, VA) were cultured in growth medium consisting of Dulbecco's modified Eagle medium (DMEM) high glucose supplemented with 10% fetal bovine serum (Sigma-Aldrich, Milan, Italy), 1% glutamine and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA), and 1% amphotericin B (Euroclone, Milan, Italy). Media was changed every other day. The cells were seeded in 35-mm dishes (Corning Life Sciences, Durham, NC) at a density of 6 3 10 5 cells/dish and differentiated, as previously described (21) . Adipocytes were used for experiments on ninth day of the initiation of differentiation. Insulin resistance was induced in 3T3-L1 adipocytes, as previously described, with slight modifications (22, 23) . Fully differentiated 3T3-L1 adipocytes were treated with growth medium supplemented with 20 nM dexamethasone and 10 mg/mL insulin for 4 days; media was changed every other day. The 3T3-L1 cells were incubated at 37°C with 5% CO 2 in each culture step.
2-Deoxyglucose uptake assay
Control and IR 3T3-L1 adipocytes in 12-well plates were washed twice and were starved for glucose by preincubating in Krebs-Ringer-Phosphate-HEPES buffer containing 2% bovine serum albumin (BSA) for 50 minutes. Following starvation, 2-deoxyglucose uptake assay was carried with Abcam (Milan, Italy) glucose uptake colorimetric assay kit, according to the manufacturer's instructions, as previously described (23) . Briefly, cells were stimulated with insulin (10 mg/mL) for 20 minutes and treated with 2-deoxyglucose, mixed, and incubated for 20 min. Each condition was performed in triplicate.
Glycerol release
The 3T3-L1 adipocytes and SAT samples were serum starved in low-glucose DMEM for 2 hours. Experiments were conducted in 4% BSA Krebs-Ringer phosphate buffer containing 136 mM NaCl, 4.7 mM KCl, 10 mM NaPO 4 (pH 7.4), 0.9 mM MgSO 4 , and 0.9 mM CaCl 2 with 10 26 M adrenaline (Monico, Venice, Italy) for 1 hour at 37°C. Reactions were stopped on ice, and media were collected and assayed for glycerol content by using free glycerol reagent (Sigma-Aldrich), according to the manufacturer's instructions. Glycerol release was normalized to cellular protein content. All values are normalized to the adrenaline-stimulated release from normal adipocytes for 3T3-L1 cells and from lean subjects for SAT. Western blot for b 2 -adrenergic receptor SAT and differentiated 3T3-L1 cells were homogenized in radioimmunoprecipitation assay lysis buffer with protease inhibitors (Sigma-Aldrich) and centrifuged at 800g for 10 minutes at 4°C, and then the middle layer was collected. Total protein content was measured by bicinchoninic acid protein assay kit (Sigma-Aldrich). Equal amounts (40 mg) of proteins were denatured in O-solution, boiled for 10 minutes, and then separated on 10% sodium dodecyl sulfate-polyacrylamide gel. Proteins were then transferred on a nitrocellulose membrane and detected by primary antibodies, respectively, rabbit polyclonal antihuman/mouse b 2 -adrenergic receptor (1:100, predicted band size 46 kDa; Abcam) and mouse monoclonal antihuman b-actin (1:1000; Abcam). Primary immune reaction was finally detected by peroxidase-conjugated secondary antibodies, followed by horseradish peroxidase substrate (KPL, Gaithersburg, MA). Protein signals were visualized by the Chemidoc XRS System (Bio-Rad, Milan, Italy).
High performance liquid chromatographymass spectrometry
The total lipid fraction from cell pellet of differentiated adipocytes from each well (approximately 6 3 10 5 cells) and 0.2 to 0.4 g ex vivo AT was extracted with a chloroform/methanol mixture (27) . After lyophilization by Vacufuge-Concentrator plus (Eppendorf, Milan, Italy), the extract was resuspended in 200 mL chloroform. The sterol fraction was isolated by solidphase extraction on a 1-mL silica column. The column was preconditioned with methanol-chloroform solution, the phospholipid component was discarded by chloroform elution, whereas the sterol fraction was eluted with acetone. The lyophilized sterol fraction was dissolved in methanol, and 20 mL was injected in the high performance liquid chromatography-mass spectrometry system. Zorbax eclipse plus C18 column (2.1 mm 3 50 mm, 1.8-mm particle size; Phenomenex, Torrance, CA) was used at the temperature of 40°C for the chromatographic step. Isocratic elution was performed by a mixture of mobile phase A: H 2 O milliQ + 0.1% formic acid (A) and methanol + 0.3% formic acid (B) in equal part (v/v). The positive ionization of the eluted simple was performed by electrospray ionization with a capillary potential of 1.50 kV. Source temperature was 100°C. Quantification of D3 and 25(OH)D was performed using the corresponding calibration curves prepared by serial dilution of each analyte (Supplemental Fig. 1 ). The data were acquired by the Mass-Lynks software using a data pitch of 0.5 seconds, and integration of mass peaks was performed with the BioPharmaLynks suite (Waters, Milford, MA). Monoisotopic mass values were determined with an accuracy ,2 ppm. Data were analyzed with MASS-LYNX Software (Waters), and total amount of both D3 and 25(OH)D was normalized on cell count for 3T3-L1 cells and on specimens weight for SAT.
Expression of vitamin D-metabolizing enzymes
Control and IR fully-differentiated adipocytes were cultured and stimulated for 4 hours with vitamin D3 and 25(OH)D, as described previously. After centrifugation, cell pellet was collected and stored at 280°C for gene expression analysis of vitamin D-metabolizing enzymes (Cyp27a1, Cyp27b1, and Vdr). Total RNA was isolated with RNeasy Mini Kit (QIAGEN, Valencia, CA), according to the manufacturer's protocol. The quality and amount of RNA isolated were determined on a NanoDrop spectrophotometer (Thermo, Wilmington, DE). A quantity amounting to 500 ng total RNA was used for first-strand complementary DNA (cDNA) synthesis using the Superscript III RT kit (Invitrogen), according to the manufacturer's instructions. Total cDNA was amplified by polymerase chain reaction using the following primers:
. Data were normalized relative to glyceraldehyde-3-phosphate dehydrogenase (forward, 5 0 -CTGCGACTTCAACAGCAACT-3 0 ; reverse, 5 0 -GAGTTGGGATAGGGCCTCTC-3 0 ). Amplification reactions were performed in a 20 mL final volume, which includes 4 mL cDNA (1:4), 10 mL 23 Power SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA), 1 mL (10 mM) each primer (forward and reverse), and 4 mL H 2 O. Amplification was carried out with an initial denaturation step at 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute using thermocycler StepOne Plus (Thermo Fisher Scientific, Carlsbad, CA). The expression ratios relative to glyceraldehyde-3-phosphate dehydrogenase were then determined by calculating DDC T , and results are expressed as fold changes compared with the endogenous control not stimulated with vitamin D. All samples were quantified in triplicate, and positive and negative controls were included in all of the reactions. Real-time data were collected by the StepOne Plus 2.1.
Subjects
This was a single-center prospective study conducted at the Unit of Endocrinology, Andrology and Reproductive Medicine at the University of Padova (Padova, Italy). The investigation was conformed to the principles of the Declaration of Helsinki, and all subjects gave informed consent to the study, which has been approved by the local ethical committee (protocol AOP0973).
We 
Statistical analysis
Statistical analysis of the data was conducted with SPSS 21.0 for Windows (SPSS, Chicago, IL). The results are expressed as means 6 standard deviation. The Kolmogorov-Smirnov test was used to check for normality of distribution. Variables not showing normal distribution were log transformed. Baseline characteristics of normal weight and obese subjects and data from in vitro experiments were compared by using unpaired Student's t tests with Bonferroni-Holm correction for multiple comparisons. Differential release of D3 and 25(OH)D was tested with the interaction between adipocyte phenotype and adrenaline in a repeated-measures analysis of variance (ANOVA). Repeated-measures ANOVA was performed to test for differences in serum 25(OH)D and PTH levels during the study at three time points (baseline, 6-month visit, endpoint). Main effects included treatment (25-hydroxyvitamin-D3 or vitamin D3), BMI status (normal weight or obese), and their interaction; age was included as a covariate, and post hoc analysis with Bonferroni-Holm correction for multiple comparisons was performed to test differences between time points. Levene's test was used to test the homogeneity of variance among groups. If homogeneity of variance assumption was violated, Welch test was performed and the respective p value was reported. Using multiple linear backward stepwise regression, we examined the relationship of the 25(OH)D increment with age, weight, BMI status, and average weekly dose for each treatment group. In the 25-hydroxyvitamin-D3 group, only BMI status and mean dose were significantly related (R 2 = 0.217, P = 0.004) and were included in the final model. In the vitamin D3 group, only weight and BMI status were included in the final model (R 2 = 0.349, P , 0.001). The proportion of vitamin D-sufficient subjects during the study was
Results
Vitamin D trafficking in cultured adipocytes
Cultured 3T3-L1 adipocytes exposed to dexamethasone and chronic insulin became IR within several days, as assessed by the ability of insulin to stimulate glucose uptake (22, 23) [ Fig. 1(a) ]. Assessment of adipocyte lipolysis was performed by measuring glycerol release. Basal (nonhormone-stimulated) lipolysis was not different between controls. Effects on hormone-stimulated lipolysis were determined by incubating the cells with 10 We quantified both D3 and 25(OH)D by high performance liquid chromatography-mass spectrometry (Supplemental Fig. 1 ). In the absence of D3 in the medium, both were undetectable (data not shown). In the absence of adrenaline, IR adipocytes showed a significantly higher uptake of D3 (P = 0.038), but a lower content of 25(OH)D (P = 0.004) compared with control adipocytes [ Fig. 1(d) ]. In adrenalinestimulated adipocytes, both D3 and 25(OH)D concentrations decreased [all P , 0.05; Fig. 1(d) ], but the lipolytic effect of adrenaline was significantly lower in IR cells for both D3 ( We evaluated the gene expression pattern of vitamin D-metabolizing enzymes before and after 4 hours of stimulation with either D3 and 25(OH)D. In control adipocytes, both Cyp27a1 and Cyp27b1, but not Vdr, were significantly upregulated after D3 stimulation (P = 0.030, P = 0.018, and P = 0.100, respectively), whereas, in IR adipocytes, Cyp27a1 expression, but not Cyp27b1 and Vdr, significantly increased compared with basal conditions (P = 0.040, P = 1.000, and P = 1.000), but to a lower extent than control adipocytes [P = 0.043; Fig. 2(a) ]. In adipocytes stimulated with 25(OH)D, Cyp27b1 and Vdr, but not Cyp27a1, were significantly upregulated from baseline in both control (P = 0.006, P = 0.015, and P = 0.897, respectively) and IR adipocytes (P = 0.046, P = 0.015, and P = 0.728), but the increment in Cyp27b1 expression was much higher in control adipocytes than in IR adipocytes [P = 0.010; Fig. 2(b) ].
Vitamin D content and release from ex vivo human adipose tissue
We assessed adrenaline-mediated lipolysis in SAT of lean and obese subjects by measuring glycerol release.
Basal (nonhormone-stimulated) lipolysis was not different between controls, and adrenaline induced a lower lipolytic response in obese SAT [ Fig. 3(a) ]. By Western blotting, we found a significantly reduced expression of b 2 -receptor in SAT from obese males [ Fig. 3(b) ].
We quantified D3 and 25(OH)D content by high performance liquid chromatography-mass spectrometry in ex vivo SAT samples from lean and obese subjects (mean BMI = 21.61 6 2.12 and 35.56 6 3.98, respectively, P , 0.001), before and after adrenaline stimulation. Lean and obese subjects did not differ for age (45.00 6 14.88 and 41.8 6 13.76, respectively, P = 0.773) and serum 25(OH)D levels (58.32 6 14.10 and 51.70 6 11.91, respectively, P = 0.446). In obese SAT, we found a higher concentration of both D3 and 25(OH)D, 
Effect of 25-hydroxyvitamin-D3 and vitamin D3 supplementation in normal weight and obese subjects
Baseline characteristics of normal weight and obese subjects are reported in Table 1 . Of the 121 subjects recruited in the study, 97 completed the treatment or had a compliance .90%. No differences in baseline parameters have emerged within groups between subjects allocated to 25-hydroxyvitamin-D3 and vitamin D3 treatment groups (all P . 0.05). In a repeated-measures ANOVA corrected for age, serum 25(OH)D levels during the study significantly incremented within each group (Table 2) , with a significant effect of treatment (F 1,92 = 14.43, P , 0.001), BMI status (F 1,92 = 55.69, P , 0.001), and their interaction (F 1,92 = 7.75, P = 0.006). PTH concentration was significantly reduced by both treatments (Table 2) . Within BMI groups, ANOVA by treatment groups adjusted for age showed that there was no significant difference in the mean serum PTH concentration between the two treatments at any time point in both normal weight and obese subjects ( Table 2) .
The increments of serum 25(OH)D achieved at the end of the study were significantly different between treatment groups and BMI status, but it was more pronounced in the obese group (Table 2 ; group-by-treatment interaction: F 1,93 = 4.94, P = 0.029). Using a multiple linear backward stepwise regression, in the 25-hydroxyvitamin-D3 group, mean dosage, but not BMI status, was a significant predictor of 25(OH)D increment (B = 0.334, 95% CI = 0.133 to 0.536, P = 0.002; B = 25.04, 95% CI = 210.521 to 0.44, P = 0.071, respectively), whereas in the vitamin D3 group, BMI status and weight were significant predictors (B = 220.696, 95% CI = 231.583 to 29.809, P , 0.001; B= 0.30, 95% CI = 20.007 to 0.607, P = 0.050, respectively). The mean dosage of 25-hydroxyvitamin-D3 during the study to achieve vitamin D sufficiency did not differ between normal weight and obese subjects ( Table 2 ; P = 0.760), whereas, in the vitamin D3 group, the mean dosage was significantly higher in obese patients compared with normal weight subjects ( Table 2 ; P , 0.001). Based on these findings, we estimated that obese subjects supplemented with vitamin D3 would require a 1.82-fold increase in weekly dosage, on average, to increase serum 25(OH)D levels by 1 nmol/L, compared with normal weight subjects (mean weekly dosage for 1-nmol/L increment = 16.99 6 3.15 and 9.35 6 3.15 mg/wk, respectively; P , 0.001), whereas, in the group supplemented with 25-hydroxyvitamin-D3, obese subjects required only a 1.11-fold increase in weekly dose compared with normal weight subjects (3.02 6 0.88 and 2.71 6 0.62 mg/wk, respectively; P = 0.174). The proportion of vitamin D-sufficient patients increased over time within all groups (all P , 0.0001), and it did not differ at any time point between normal weight subjects treated with either 25-hydroxyvitamin-D3 or vitamin D3 [all P . 0.05; Fig. 4(a) ], whereas the proportion of obese patients with 25(OH)D .50 nmol/L was significantly higher after 6 months of treatment with 25-hydroxyvitamin-D3 compared with vitamin D3, but not at the end of the study [P = 0.003 and P = 0.125, respectively; Fig. 4(b) ].
Discussion
In this study, we analyzed a range of biological processes associated with vitamin D metabolism in either 3T3-L1 adipocytes rendered IR or fat explants from obese male subjects. We observed a considerable reduction in adrenaline-stimulated lipolytic release of vitamin D3 and 25(OH)D in all models, which might be explained by a reduced expression of b 2 -adrenergic receptor in both human and 3T3-L1 models. However, the mechanisms controlling the deposition and release of vitamin D from AT are still unknown (17) . It is likely that, because vitamin D is a fat-soluble secosteroid, it is subjected to the same pathway of cathecolamine-induced lipolysis observed for cholesterol (18) . Interestingly, we observed that adipocytes were capable of converting loaded D3 into 25(OH)D, but to a lesser extent in IR adipocytes, which was supported by reduced expression of 25-hydroxylating enzyme Cyp27a1. Finally, supplementation with oral 25-hydroxyvitamin-D3 was more rapid in achieving vitamin D sufficiency in obese patients than vitamin D3. These findings demonstrate a clear alteration of vitamin D uptake and release in pathological AT.
The fat solubility of vitamin D suggests a sequestration process in body fat depots, leading to lower bioavailability in the obese state (6), which is further promoted by catecholamine-and natriuretic peptide-lipolytic resistance in both obese patients (14) and IR adipocytes (15) , possibly leading to a reduced release of vitamin D from AT, given the fat-soluble secosteroid nature of vitamin D.
We confirmed that IR 3T3-L1 cells had a reduced glucose uptake (22, 23, 31) and adrenaline-induced lipolytic response (32), compared with control adipocytes, in concordance with previous studies demonstrating abrogated catecholamine-induced lipolysis in adipocytes from obese subjects [reviewed by Arner and Langin (33)], and we showed reduced protein expression of b 2 -adrenergic receptor expression in both 3T3-L1 cells with insulin resistance and SAT from obese subjects.
In vitro and in vivo data suggest that catecholamine resistance is restricted to the b 2 -adrenoceptor, which may be due to a decreased number and function of b 2 -adrenoceptors (34). We confirmed this hypothesis, showing reduced levels of b 2 -adrenoceptor in both IR 3T3-L1 and obese SAT, although the exact mechanism associated with this decrement needs to be further elucidated. Indeed it has been shown that impaired lipolysis in AT does not improve after weight loss (35) , is a feature of childhood onset obesity (36) , and affects adipocytes from first-degree relatives of obese subjects (37) . These data indicate that catecholamine resistance may be an important factor causing obesity, rather than a consequence. In fact more evidence comes from polymorphisms in genes encoding key proteins of the lipolytic pathway [reviewed by Jocken and Blaak (32) ]. Based on the well-established reduction in catecholamine resistance and 25(OH)D levels in the obese state, we aimed to verify whether the AT is not only a passive storage, but also actively sequestrates vitamin D, due to its reduced lipolytic response. After incubation with D3, IR 3T3-L1 cells showed an increased intracellular content of D3 compared with control adipocytes, but we also showed a lower concentration of 25(OH)D in these cells; therefore, the increased amount of D3 in IR cells could actually be the result of a greater conversion of D3 in 25(OH)D in control adipocytes, rather than a greater uptake in IR fat cells. Both D3 and 25(OH)D decreased after adrenalineinduced lipolysis, but the rate of decline was significantly lower in IR fat cells. In contrast, in 3T3-L1 incubated with 25(OH)D, D3 was undetectable, as expected, and 25(OH)D content was higher in IR adipocytes. In the presence of adrenaline, in both control and IR cells, Notably, independently of the adipocyte phenotype, the absolute uptake of 25(OH)D was lower than the uptake of D3, despite the same concentration of both forms in the incubation medium. This could be explained by the different lipo-solubility of the two forms, where D3 has a higher partition coefficient (logK ow = 10.2) than 25(OH)D (logK ow = 8.43). This would explain also why in vivo D3 is mainly found in fat (approximately 75%), whereas 25(OH)D is more equally distributed (approximately 35% in fat) (10, 38) , although in this case vitamin D-binding protein affinity must be taken into consideration, because it is lower for D3 than 25(OH)D (39); therefore, more unbound D3 could freely diffuse into AT given its higher lipo-solubility.
As confirmed by our observation of significant amounts of 25(OH)D in adipocytes loaded with D3, 25-hydroxylation was already shown to be functional in AT due to the presence of Cyp27a1, which is upregulated by D3 treatment (40) . In accordance, we found upregulation of Cyp27a1 after D3 stimulation, but it was less pronounced in IR adipocytes, which could explain the reduced conversion of D3 into 25(OH)D in these cells. Cyp27b1 was already shown to be functional in 3T3-L1 adipocytes (41) , but at lower levels in SAT from obese (42) . We found that its stimulation was reduced in IR adipocytes; this would imply a reduced capacity to synthesize 1,25(OH)D(7) and clearly requires further investigation. Notably, in both IR and control adipocytes, Vdr was upregulated by 25(OH)D. Recently, evidence was provided that 25(OH)D is an agonist for Vdr and exhibited direct gene regulatory properties (43) . Because it was shown that protein levels of Cyp27b1 and Vdr measured by Western blotting were consistent with mRNA levels (44, 45) , these results can also be extended at a protein level, thus suggesting that autocrine/paracrine actions of vitamin D in AT could be altered (19) .
Previous in vitro results were confirmed also in ex vivo explants of SAT from obese and lean subjects. The 25(OH)D concentration was lower than D3, and both were comparable with previous reports from human AT measured by LC-MS (12, 46) . Adrenaline-stimulated SAT had lower content of both D3 and 25(OH)D than unstimulated SAT, but the reduction was significantly more pronounced in SAT from lean subjects. The reduced bioavailability of vitamin D in obese individuals probably involves active sequestration in AT, due to a reduced catecholamineinduced release of both D3 and 25(OH)D, rather than an active uptake, and altered autocrine/paracrine actions due to altered activity of vitamin D-metabolizing enzymes. d Significant differences during the study within each group were investigated by ANOVA for repeat measures with age as a covariate.
e Significant differences between treatment groups were tested with ANOVA with age as a covariate; fixed factors: treatment and BMI status.
f P , 0.001 vs vitamin D3 dose in normal weight subjects.
Finally, in a cohort of vitamin D-deficient subjects randomly assigned to supplementation with either 25-hydroxyvitamin-D3 or vitamin D3, we found that normal weight subjects had comparable responses to either treatment. Conversely, the proportion of obese subjects achieving vitamin D sufficiency was significantly higher after 6 months of supplementation with 25-hydroxyvitamin-D3, suggesting a more rapid effect of this treatment. Because, at the 6-month follow-up, in patients that had not achieved serum 25(OH)D levels.50 nmol/L the dosage was increased by 50%, we estimated that obese subjects supplemented with vitamin D3 would require an almost twofold increase in weekly dosage to increase serum 25(OH)D levels by 1 nmol/L, which is comparable with previous reports (29, 47) . All of these aspects must be taken into consideration when evaluating the most appropriate treatment in vitamin D-deficient subjects affected by obesity.
In conclusion, this study shows the following: (1) a reduced release of D3 and 25(OH)D in IR 3T3-L1 and SAT from obese subjects after adrenaline-induced lipolysis, concomitant with lower expression of b 2 -adrenoceptor; (2) a reduced response of vitamin D-metabolizing genes to D3 and 25(OH)D stimulation in IR 3T3-L1; and (3) an increased effectiveness of 25-hydroxyvitamin-D3 supplementation in increasing vitamin D levels in obese patients, compared with vitamin D3, after intrinsic effectiveness was accounted for. Further studies are needed to elucidate the molecular mechanisms controlling the deposition and release of vitamin D from AT.
